Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by nodaytraderon Dec 30, 2021 1:07pm
92 Views
Post# 34271335

RE:RE:Trading December 29

RE:RE:Trading December 29I agree with you that value investors in Algernon are in dire straits if an American stock exchange (NASDAQ) does not rescue this Canadian company.

However, value investors will not be the only losers. Algernon is engaged in research that, if successful, will bring relief from pain and suffering to millions of people around the world.

Algernon's ability to raise capital for research is directly related to its share price. So, if the share is  depressed, it will cause unnecessary suffering and is, therefore, a public policy issue. As such, responsible authorities should be examining the issue to determine whether any aspect of the price depression is contrived or artificial and thus should be regulated or proscribed.

But no one seems to looking - not OSFI or IIROC or the CSE or any MP.  I know becaudse I have asked them all.

<< Previous
Bullboard Posts
Next >>